C3.ai (NYSE:AI | AI Price Prediction) currently trades at $10.18, while Wedbush Securities analyst Dan Ives carries a Street-high price target of $15 on the enterprise AI software company, implying roughly 47% upside from here. That headline number sits far above the broader Wall Street consensus, which has drifted lower after a brutal fiscal 2026.
C3.ai sells the C3 Agentic AI Platform and industry-specific enterprise AI applications, competing for federal, defense, and industrial AI dollars. Founder Thomas Siebel returned as CEO in June and personally bought 6.17 million shares at $11.16, betting his own capital on a turnaround.
A Revenue Collapse the Market Refuses to Look Past
Fiscal 2026 revenue landed at $250.27 million, down 35.67% year over year, with Q4 showing revenue of $51.60 million, a 52.5% year-over-year decline. GAAP gross margin collapsed from 62% to 22%, and full-year free cash flow deteriorated to negative $192.14 million.
Siebel called the recent sales performance “unspeakably horrible” and said “sales just fell off the cliff” across the last five quarters. FY2027 revenue guidance of $210 million to $240 million implies further shrinkage before recovery. Shares are off 45.27% over the past year and 24.48% year to date. Securities class actions emerged after the Q1 FY2026 disclosure around Siebel’s earlier health issues.
Why Ives and Wedbush Are Still Betting on a 50% Rebound
Ives maintains an Outperform rating with the $15 target, the Street-high across all coverage. His thesis rests on three pillars: C3.ai as an early enterprise pure-play for federal and commercial generative AI adoption, the shift toward consumption-based pricing to lower deployment friction, and a partner-led motion through Microsoft Azure, AWS, and Google Cloud.
Q3 FY2026 bookings from federal, defense, and aerospace grew 134% year over year and reached 55% of total bookings. The joint qualified pipeline with Microsoft grew 146% year over year, and the AWS joint pipeline grew 172%. That aligns with a Pentagon budget request calling for $58.5 billion for AI in FY2027.
Broader Wall Street remains skeptical. Of 14 covering analysts, the breakdown is 0 Strong Buy, 1 Buy, 7 Hold, 3 Sell, and 3 Strong Sell, with an average target of just $8.82, below the current quote. Siebel’s message was blunt: “Game on.”
How C3.ai Stacks Up Against Its AI Software Peers
AI software names with real revenue growth have held up while C3.ai has been isolated.
Palantir (NASDAQ:PLTR) trades near $178.65 against a $191.68 target, roughly 7% upside. Q2 revenue climbed 92.8% to $1.94 billion, and 20 Buys against 10 Holds reflect steady enthusiasm.
SoundHound AI (NASDAQ:SOUN) sits near $7.98 with a $12.71 target, implying roughly 59% upside. Six Buys and two Holds, with Q2 revenue up 45% to $61.9 million.
BigBear.ai (NYSE:BBAI) trades near $3.26 against a $4 consensus, or about 23% upside. Coverage is thin at one Buy and two Holds.
Ives’ $15 call on C3.ai represents a wider gap than any peer average, signaling the market treats C3.ai as an execution story rather than a sector story.
The Data Behind a Bearish Consensus and a Bold Outlier
C3.ai trades at $10.18 with a $8.82 consensus target across 14 analysts, meaning the average view implies roughly 13% downside. Ives’ $15 target drives the 50% upside narrative.
Shares are down 24.48% year to date while the S&P 500 has gained 14.07%, a staggering relative gap. Beta sits at 2.07, and Polymarket bettors put implied bankruptcy odds by year-end 2026 at 13.5%, down from a month earlier.
My Take: A Deep Value Bet on One Man’s Reputation
The bull case strengthens if the Siebel-led restructuring shows quantifiable sales productivity gains within two quarters, federal bookings continue tracking at more than half of total, and Microsoft and AWS partner pipelines convert into recognized revenue. Ives’ $15 target requires that trajectory to materialize before FY2028.
The bear case builds if Q1 FY2027 misses the $50 million to $54 million guide, gross margin fails to recover from 22%, or class action litigation escalates. With free cash flow at negative $192 million and cash burn accelerating, patience has a cost.
The skeptical lean prevails. Siebel’s insider buy and blunt accountability are genuine positives, but the average analyst target sitting below the current price tells you where the weight of evidence rests. This is a turnaround bet, and the market is charging full price to take it.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks